ARCA biopharma to Present at Rodman & Renshaw Tenth Annual Healthcare Conference
November 06 2008 - 6:30AM
PR Newswire (US)
Webcast Presentation Scheduled for Wednesday, November 12, 2008 at
11:10 a.m. EST BROOMFIELD, Colo. and SAN CARLOS, Calif., Nov. 6
/PRNewswire-FirstCall/ -- ARCA biopharma, Inc., a biopharmaceutical
company developing genetically-targeted therapies for heart failure
and other cardiovascular diseases, and Nuvelo, Inc. (NASDAQ:NUVO)
today announced that Michael Bristow, M.D., Ph.D., ARCA's chairman
and chief science and medical officer, will present at the Rodman
& Renshaw Tenth Annual Healthcare Conference on Wednesday,
November 12, 2008, at 11:10 a.m. EST in New York City. ARCA
biopharma and Nuvelo, Inc. announced on September 25, 2008 that
they have entered into a definitive merger agreement, expected to
create a cardiovascular-focused, late-stage biotechnology company.
The presentation will discuss the assets of both companies,
including ARCA's lead product Gencaro(TM) (bucindolol
hydrochloride) a near-term commercial opportunity, as well as
Nuvelo's mid-stage pipeline asset, novel short-acting anticoagulant
NU172, to drive long-term growth. ARCA recently announced that the
FDA has accepted for filing a New Drug Application for Gencaro. The
presentation will also discuss the structure and strategic plan of
the combined company, pending the closing of the merger. A live
audio webcast of the presentation will be available online via the
ARCA biopharma website at http://www.arcabiopharma.com/ or the
Investor Relations portion of Nuvelo's website at
http://www.nuvelo.com/. About ARCA biopharma ARCA biopharma, Inc.
is a privately held company focused on developing and
commercializing genetically targeted therapies for heart failure
and other cardiovascular diseases. The Company's lead product
candidate, Gencaro(TM) (bucindolol hydrochloride), is an
investigational pharmacologically unique beta-blocker and mild
vasodilator being developed for heart failure and other
indications. ARCA has identified common genetic variations that
predict individual patient response to Gencaro. The NDA for
Gencaro, including the proposed brand name, is under review by FDA.
The companion genetic test for Gencaro is in development by ARCA's
partner, Laboratory Corporation of America. For more information
please visit http://www.arcabiopharma.com/. About Nuvelo Nuvelo,
Inc. is dedicated to improving the lives of patients through the
discovery, development and commercialization of novel drugs for
acute cardiovascular disease, cancer and other debilitating medical
conditions. Nuvelo's development pipeline includes NU172, a direct
thrombin inhibitor which has completed Phase 1 development for use
as a potential short-acting anticoagulant during medical or
surgical procedures; and NU206, a Wnt pathway modulator in Phase 1
development for the potential treatment of chemotherapy/radiation
therapy-induced mucositis and inflammatory bowel disease. In
addition, Nuvelo is pursuing research programs in leukemia and
lymphoma therapeutic antibodies and Wnt signaling pathway
therapeutics to further expand its pipeline and create additional
partnering and licensing opportunities. Information about Nuvelo is
available at its website at http://www.nuvelo.com/ or by phoning
650-517-8000. Forward-looking statements This press release
contains "forward-looking statements" which include, without
limitation, statements regarding the completion of the proposed
merger transaction between Nuvelo, ARCA and Dawn Acquisition Sub,
Inc., the transaction's anticipated benefits, timing, progress and
anticipated completion of the combined company's clinical stage and
research programs, which statements are hereby identified as
"forward-looking statements" for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
Such statements are based on the companies' managements' current
expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward- looking statements as a result of many factors, including,
without limitation, failure of Nuvelo or ARCA's stockholders to
approve the merger, the ability to complete the transaction
contemplated by this communication in a timely fashion, the risk
that Nuvelo's and ARCA's business operations will not be integrated
successfully; the combined company's inability to further identify,
develop and achieve commercial success for products and
technologies; the risk that the combined company's financial
resources will be insufficient to meet the combined company's
business objectives; uncertainties relating to drug discovery and
the regulatory approval process; clinical development processes;
enrollment rates for patients in the companies' clinical trials;
changes in relationships with strategic partners and dependence
upon strategic partners for the performance of critical activities
under collaborative agreements; and the impact of competitive
products and technological changes. These and other factors are
identified and described in more detail in Nuvelo's filings with
the SEC, including without limitation Nuvelo's quarterly report on
Form 10-Q for the quarter ended June 30, 2008 and subsequent
filings. We disclaim any intent or obligation to update these
forward-looking statements. Additional Information and Where to
Find It Nuvelo has filed a registration statement on Form S-4, and
a related proxy statement/prospectus/consent solicitation, in
connection with the merger. Investors and security holders are
urged to read the registration statement on Form S-4 and the
related proxy statement/prospectus/consent solicitation which
contain important information about the merger transaction.
Investors and security holders may obtain free copies of these
documents and other documents filed with the SEC at the SEC's
website at http://www.sec.gov/. In addition, investors and security
holders may obtain free copies of the documents filed with the SEC
by contacting Nuvelo Investor Relations at the email address: or by
phone at 650-517-8000. In addition to the registration statement
and related proxy statement/prospectus/consent solicitation, Nuvelo
files annual, quarterly and special reports, proxy statements and
other information with the SEC. You may read and copy any reports,
statements or other information filed by Nuvelo, Inc. at the SEC
public reference room at 100 F Street, N.E., Washington, D.C.
20549. Please call the SEC at 1-800-SEC-0330 for more information.
Please call the SEC at 1-800-SEC-0330 for further information on
the public reference room. Nuvelo, Inc.'s filings with the SEC are
also available to the public from commercial document-retrieval
services and at SEC's website at http://www.sec.gov/, and from
Investor Relations at Nuvelo as described above. This communication
shall not constitute an offer to sell or the solicitation of an
offer to sell or the solicitation of an offer to buy any
securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended. Nuvelo, ARCA and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from the stockholders of Nuvelo in connection with the
merger transaction. Information regarding the special interests of
these directors and executive officers in the merger transaction is
included in the proxy statement/prospectus/consent solicitation
described above. Additional information regarding the directors and
executive officers of Nuvelo is also included in Nuvelo's proxy
statement for its 2008 Annual Meeting of Stockholders which was
filed with the SEC on April 23, 2008 and its Annual Report on Form
10-K for the year ended December 31, 2007, which was filed with the
SEC on March 12, 2008. These documents are available as described
above. DATASOURCE: ARCA biopharma, Inc., Nuvelo, Inc. CONTACT: Greg
Gin of Invigorate Communications, Inc., +1-908-376-7737, ; or
Danielle Bertrand of WeissComm Partners, Inc., +1-415-946-1056, ;
both for ARCA biopharma, Inc., and Nuvelo, Inc. Web site:
http://www.arcabiopharma.com/ http://www.nuvelo.com/
Copyright
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jul 2023 to Jul 2024